Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Common Equity: 2018-2024

Historic Common Equity for Legend Biotech (LEGN) over the last 7 years, with Dec 2024 value amounting to $1.0 billion.

  • Legend Biotech's Common Equity fell 12.57% to $1.0 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $1.0 billion, marking a year-over-year decrease of 12.57%. This contributed to the annual value of $1.0 billion for FY2024, which is 16.85% down from last year.
  • Legend Biotech's Common Equity amounted to $1.0 billion in FY2024, which was down 16.85% from $1.3 billion recorded in FY2023.
  • In the past 5 years, Legend Biotech's Common Equity registered a high of $1.3 billion during FY2023, and its lowest value of $597.8 million during FY2020.
  • Its 3-year average for Common Equity is $1.0 billion, with a median of $1.0 billion in 2024.
  • In the last 5 years, Legend Biotech's Common Equity soared by 295.03% in 2020 and then declined by 16.85% in 2024.
  • Over the past 5 years, Legend Biotech's Common Equity (Yearly) stood at $597.8 million in 2020, then increased by 28.13% to $765.9 million in 2021, then declined by 2.82% to $744.3 million in 2022, then spiked by 68.12% to $1.3 billion in 2023, then dropped by 16.85% to $1.0 billion in 2024.